OpGen's Principal Scientist Dr. Matthias Klein Has Presented Results From The Clinical Trial For Its Unyvero Urinary Tract Infection Panel During ASM Microbe's In Depth Symposium Session 'The Year In Clinical Microbiology'
Portfolio Pulse from Benzinga Newsdesk
OpGen's Principal Scientist, Dr. Matthias Klein, presented results from the clinical trial for its Unyvero Urinary Tract Infection (UTI) panel at ASM Microbe's symposium. The Unyvero UTI panel tests for various bacterial and fungal pathogens and antimicrobial resistance markers directly from urine specimens.
June 20, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OpGen's Unyvero UTI panel clinical trial results were presented by Dr. Matthias Klein, potentially leading to increased interest in the product.
The presentation of the clinical trial results for OpGen's Unyvero UTI panel by Dr. Matthias Klein at a reputable symposium can potentially increase interest in the product. This may lead to higher demand and positively impact OpGen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100